View Older Stories View More Recent Stories

Aug 30, 2019 08:00AM The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
Aug 26, 2019 04:05PM Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
Aug 6, 2019 04:05PM Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
Aug 1, 2019 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 29, 2019 04:05PM Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
Jun 25, 2019 04:01PM Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
May 8, 2019 04:05PM Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
Apr 30, 2019 04:05PM Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
Apr 15, 2019 04:32PM Paratek Pharmaceuticals (PRTK) Broadens Clinical Profile of NUZYRA with New ECCMID Data Presentations
Apr 15, 2019 04:30PM Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
Apr 4, 2019 08:30AM Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
Apr 1, 2019 09:05AM Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
Mar 28, 2019 08:00AM Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
Mar 18, 2019 08:10AM Paratek Pharmaceuticals (PRTK) CFO Douglas Pagan Resigns
Mar 18, 2019 08:00AM Paratek Pharmaceuticals Announces Management Change
Mar 1, 2019 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2019 08:00AM Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Feb 27, 2019 04:01PM Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 14, 2019 04:05PM Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Feb 13, 2019 04:05PM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
Feb 6, 2019 05:05PM New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
Feb 5, 2019 04:05PM Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
Feb 1, 2019 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan 2, 2019 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 3, 2018 04:01PM Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
Nov 27, 2018 08:10AM Paratek Pharmaceuticals (PRTK) Reports First Patient Dosing in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis
Nov 27, 2018 08:00AM Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
Nov 6, 2018 04:02PM Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
Nov 1, 2018 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 26, 2018 04:05PM Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
Oct 4, 2018 04:01PM Paratek Pharmaceuticals (PRTK) Acceptance of European MAA for Oral and Intravenous Omadacycline
Oct 4, 2018 04:01PM Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
Oct 3, 2018 04:05PM Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
Oct 2, 2018 07:27PM Paratek Pharmaceuticals (PRTK) NUZYRA Approved by the FDA
Oct 2, 2018 06:37PM Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
Oct 2, 2018 08:48AM Paratek Pharmaceuticals (PRTK) Announces FDA Approval for SEYSARA to Treat Moderate to Severe Acne
Oct 2, 2018 08:45AM FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne
Oct 1, 2018 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2018 08:00AM Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018
Sep 4, 2018 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Aug 29, 2018 04:05PM Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
Aug 8, 2018 02:21PM Paratek Pharmaceuticals (PRTK) Confirms Positive FDA Ad Comm Recommendation for Omadacycline
Aug 8, 2018 02:20PM FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
Aug 8, 2018 07:06AM Paratek Pharmaceuticals (PRTK) Reports Trading Halt Ahead of Today's FDA Panel on Omadacycline
Aug 8, 2018 07:05AM Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial
Aug 2, 2018 04:01PM Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
Jul 23, 2018 07:30AM Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
Jun 20, 2018 09:06AM Paratek Pharmaceuticals (PRTK) Announces FDA Advisory Committee for Omadacycline Set for August 8
Jun 20, 2018 09:05AM Paratek Announces FDA Advisory Committee Date for Omadacycline
Jun 11, 2018 08:03AM Paratek Pharmaceuticals (PRTK) Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
View More Recent Stories View Older Stories